Please assess the completion status of the following clinical trial:

Trial Title: Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV negative person, who was assigned male or female at birth, who reports sex with another man in the last year and is in good general health~2. Aged 18-59 years~3. Not currently taking PrEP and no plans to initiate during study~4. Not currently taking PEP~5. Not currently taking doxycycline or other tetracycline-derived antibiotics and no plans to initiate during the study~6. Willing to use condoms consistently for the duration of the study~7. Able to provide informed consent in English~8. No plans for relocation in the next 4 months~9. Willing to undergo peripheral blood, urine, rectal or vaginal secretion collection, and a rectal or vaginal and cervical biopsy procedure~10. Willing to use study products as directed~11. Hepatitis B surface antigen (HBsAg) negative (screening lab test)~12. Creatinine clearance \>60 ml/min~Exclusion Criteria:~1. Currently infected with hepatitis virus and/ or has liver disease~2. Current or chronic history of kidney disease or creatinine clearance (CrCl)\<60 ml/min~3. Continued need for, or use during the 90 days prior to enrollment, of the following medications:~   1. Systemic immunomodulatory agents~  2. Supraphysiologic doses of steroids (short course steroids less than 7 days duration, allowable at the discretion of the investigators)~  3. Chemotherapy or radiation for treatment of malignancy~  4. Experimental medications, vaccines, or biologicals~4. Intent to use HIV antiretroviral pre/post-exposure prophylaxis (PrEP or PEP) during the study, outside of the study procedures~5. Intent to use doxycycline or other tetracycline-derived antibiotics during the course of the study, outside of the study procedures~6. Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements~7. Not pregnant and no plans on getting pregnant throughout the duration of the study~8. Known allergic reaction to study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Doxycycline and Biktarvy (Type: EXPERIMENTAL): Participants will take both study drugs simultaneously at home approximately 1 hour before Visit 2 and will be instructed to take a timestamped photograph or videotape of themselves taking the dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).